Mankind Pharma Limited has informed the Exchange regarding Cessation of Mr Sanjay Koul as Other of the company w.e.f. July 31, 2025.
MANKIND · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Mankind Pharma reported Q1 FY26 (quarter ended June 30, 2025) standalone revenue of ₹2,541.36 crores (up from ₹2,412.62 crores YoY) and standalone PAT of ₹412.76 crores (up from ₹382.46 crores YoY). Consolidated revenue grew sharply to ₹3,570.35 crores (from ₹2,867.85 crores), but consolidated PAT fell to ₹444.62 crores (from ₹543.07 crores), likely due to higher finance and depreciation costs post the BSV acquisition. The board declared an interim dividend of ₹1 per share (100% on face value), with record date August 8, 2025. It also approved acquiring the Women Health Rx branded generics business of its wholly-owned subsidiary BSV via slump sale, raising up to ₹1,000 crores via commercial papers, and reclassifying Ayushi and Poonam Estates LLP from promoter group to public category. Additionally, Dr. Sanjay Koul, Chief Marketing Officer, resigned effective end of August 1, 2025.
Mixed signals for shareholders: solid standalone growth and a 100% interim dividend are positive, but the consolidated PAT decline and ongoing income tax proceedings (₹1,825+ crores in disallowances under appeal) may weigh on sentiment. The CMO exit adds a short-term leadership gap, though it's a senior management role rather than the CEO/CFO. The BSV Women Health acquisition and CP fundraising indicate continued aggressive expansion leveraging the BSV platform.